SPAIR technique in oncoplastic breast surgery: The first case series

2016 ◽  
Vol 42 (5) ◽  
pp. S55
Author(s):  
Rosa Di Micco ◽  
Rachel O'Connell ◽  
Jennifer Rusby ◽  
Peter A. Barry
Keyword(s):  
Breast Surgery ◽  
Case Series ◽  
Oncoplastic Breast Surgery ◽  
First Case

De-escalation of complexity in oncoplastic breast surgery: Case series from a specialized breast center

The Breast ◽  
2019 ◽  
Vol 46 ◽  
pp. 12-18 ◽  
Author(s):  
G. Catanuto ◽  
A. Khan ◽  
V. Ursino ◽  
E. Pietraforte ◽  
G. Scandurra ◽  
...  
Keyword(s):  
Breast Surgery ◽  
Case Series ◽  
Oncoplastic Breast Surgery ◽  
Breast Center

scholarly journals An alternative to standard lumpectomy: a 5-year case series review of oncoplastic breast surgery outcomes in a Canadian setting

2020 ◽  
Vol 63 (1) ◽  
pp. E46-E51 ◽  
Author(s):  
Sarah Knowles ◽  
Jessica Maxwell ◽  
Alycya Lumsden ◽  
Lydia Pearson ◽  
Jessica Pulhin ◽  
...  
Keyword(s):  
Breast Surgery ◽  
Case Series ◽  
Oncoplastic Breast Surgery ◽  
Surgery Outcomes ◽  
Canadian Setting

scholarly journals Objective assessment of clinical, oncological and cosmetic outcomes following volume replacement in patients undergoing oncoplastic breast-conserving surgery: protocol for a systematic review

BMJ Open ◽  
2018 ◽  
Vol 8 (7) ◽  
pp. e020859 ◽  
Author(s):  
Jesse Hu ◽  
Richard M Rainsbury ◽  
Ashvina Segaran ◽  
Oana Predescu ◽  
Pankaj G Roy
Keyword(s):  
Systematic Review ◽  
Breast Surgery ◽  
Objective Assessment ◽  
Case Series ◽  
Breast Conserving Surgery ◽  
Volume Replacement ◽  
Case Control Studies ◽  
Oncoplastic Breast Surgery ◽  
Patient Reported ◽  
Cosmetic Outcomes

IntroductionOncoplastic breast surgery allows the excision of larger tumours without compromising cosmetic outcome and can be broadly divided into volume displacement and volume replacement techniques. Although oncoplastic surgery has rapidly gained acceptance and is now widely practised, evidence is still lacking especially in patients who underwent volume replacement techniques. As it is a relatively new technique that has been described in the literature in the recent years, a summary of evidence from this literature can help clinicians to understand the clinical, oncologicalandcosmetic outcomes of such procedures.Methods and analysisAll original studies including randomised controlled trials, cohort studies, case–control studies and case series involving more than 10 women undergoing partial breast reconstruction using a volume replacement technique will be included. The primary objective is to evaluate the clinical, oncological and cosmetic outcomes following volume replacement in patients undergoing oncoplastic breast-conserving surgery. The secondary objective is to review the patient-reported outcomes (PROMs) associated with oncoplastic breast surgery to help identify any unmet needs and to consider refining the existing PROMs to suit women undergoing volume replacement surgery.A comprehensive literature search, eligibility assessment and extraction of data will be conducted by two trained teams acting independently. Data will be extracted and stored in a database with standardised extraction fields to facilitate easy and consistent data entry. Heterogeneity will be assessed using the Cochrane tests.Ethics and disseminationThis systematic review requires no ethical approval. It will be published in a peer-reviewed journal, and it will also be presented at nationalandinternational conferences.PROSPERO registration numberCRD42017075700; Pre-results.

scholarly journals Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Hereditary Podocytopathies, Alport Syndrome, and FSGS: A Case Series to Better Plan a Large-Scale Study

Cells ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1815
Author(s):  
Jan Boeckhaus ◽  
Oliver Gross
Keyword(s):  
Glomerular Filtration ◽  
Alport Syndrome ◽  
Large Scale ◽  
Case Series ◽  
Hereditary Diseases ◽  
Glomerular Filtration Barrier ◽  
Early Effect ◽  
Filtration Barrier ◽  
First Case ◽  
Sodium Glucose Cotransporter

Hereditary diseases of the glomerular filtration barrier are characterized by a more vulnerable glomerular basement membrane and dysfunctional podocytes. Recent clinical trials have demonstrated the nephroprotective effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in chronic kidney disease (CKD). SGLT2-mediated afferent arteriole vasoconstriction is hypothesized to correct the hemodynamic overload of the glomerular filtration barrier in hereditary podocytopathies. To test this hypothesis, we report data in a case series of patients with Alport syndrome and focal segmental glomerulosclerosis (FSGS) with respect of the early effect of SGLT2i on the kidney function. Mean duration of treatment was 4.5 (±2.9) months. Mean serum creatinine before and after SGLT-2i initiation was 1.46 (±0.42) and 1.58 (±0.55) mg/dL, respectively, with a median estimated glomerular filtration rate of 64 (±27) before and 64 (±32) mL/min/1.73 m2 after initiation of SGLT2i. Mean urinary albumin-creatinine ratio in mg/g creatinine before SGLT-2i initiation was 1827 (±1560) and decreased by almost 40% to 1127 (±854) after SGLT2i initiation. To our knowledge, this is the first case series on the effect and safety of SGLT2i in patients with hereditary podocytopathies. Specific large-scale trials in podocytopathies are needed to confirm our findings in this population with a tremendous unmet medical need for more effective, early on, and safe nephroprotective therapies.

Breast MRI in DCIS size estimation, breast-conserving surgery and oncoplastic breast surgery

2021 ◽  
Vol 94 ◽  
pp. 102158
Author(s):  
Alexander Bartram ◽  
Fiona Gilbert ◽  
Alastair Thompson ◽  
G Bruce Mann ◽  
Amit Agrawal
Keyword(s):  
Breast Surgery ◽  
Breast Mri ◽  
Breast Conserving Surgery ◽  
Size Estimation ◽  
Oncoplastic Breast Surgery

scholarly journals Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid

2021 ◽  
Vol 10 (9) ◽  
pp. 1916
Author(s):  
Ágnes Kinyó ◽  
Anita Hanyecz ◽  
Zsuzsanna Lengyel ◽  
Dalma Várszegi ◽  
Péter Oláh ◽  
...  
Keyword(s):  
Bullous Pemphigoid ◽  
Clinical Laboratory ◽  
Case Series ◽  
Dipeptidyl Peptidase ◽  
Area Index ◽  
Histological Features ◽  
Dipeptidyl Peptidase 4 ◽  
First Case ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
The Mean

Bullous pemphigoid (BP) is an autoimmune blistering disease of elderly patients that has shown increasing incidence in the last decades. Higher prevalence of BP may be due to more frequent use of provoking agents, such as antidiabetic dipeptidyl peptidase-4 inhibitor (DPP4i) drugs. Our aim was to assess DPP4i-induced bullous pemphigoid among our BP patients and characterize the clinical, laboratory and histological features of this drug-induced disease form. In our patient cohort, out of 127 BP patients (79 females (62.2%), 48 males (37.7%)), 14 (9 females and 5 males) were treated with DPP4i at the time of BP diagnosis. The Bullous Pemphigoid Disease Area Index (BPDAI) urticaria/erythema score was significantly lower, and the BPDAI damage score was significantly higher in DPP4i-BP patients compared to the nonDPP4i group. Both the mean absolute eosinophil number and the mean periblister eosinophil number was significantly lower in DPP4i-BP patients than in nonDPP4i cases (317.7 ± 0.204 vs. 894.0 ± 1.171 cells/μL, p < 0.0001; 6.75 ± 1.72 vs. 19.09 ± 3.1, p = 0.0012, respectively). Our results provide further evidence that DPP4i-associated BP differs significantly from classical BP, and presents with less distributed skin symptoms, mild erythema, normal or slightly elevated peripheral eosinophil count, and lower titers of BP180 autoantibodies. To our knowledge, this is the first case series of DPP4i-related BP with a non-inflammatory phenotype in European patients.

Sign in / Sign up

Export Citation Format

Share Document